title: Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone.
abstract: Hepatic veno-occlusive disease (VOD) is one of the most common and important regimen-related toxicities observed after hematopoietic stem cell transplantation (HSCT). There are no universally accepted preventative or therapeutic approaches for VOD. We prospectively evaluated the safety and efficacy of a short course of methylprednisolone (MP) in 48 patients undergoing allogeneic HSCT who were diagnosed with hepatic VOD. MP was administered at a dose of 0.5 mg/kg i.v. every 12 h for a total of 14 doses, and then discontinued without taper. Thirty (63%) patients responded with a reduction in total serum bilirubin of 50% or more after 10 days of treatment. In univariate analysis, non-responders had a higher total bilirubin at the start of MP therapy, more weight gain, evidence of fungal infection and platelet refractoriness. High SGPT and early engraftment were significant factors among responders. Twenty-five of the 30 responders survived up to day +100, whereas all but three non-responders died within 100 days post-HSCT, for a probability of survival of 58% among responders and 10% for non-responders. Prospective comparative studies are needed to confirm the observed encouraging outcome of MP therapy for VOD.
authors.affiliation: King Faisal Cancer Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
authors.forename: A
authors.initials: A
authors.lastname: Al Beihany
authors.forename: H
authors.initials: H
authors.lastname: Al Omar
authors.forename: E
authors.initials: E
authors.lastname: Sahovic
authors.forename: N
authors.initials: N
authors.lastname: Chaudhri
authors.forename: F
authors.initials: F
authors.lastname: Al Mohareb
authors.forename: F
authors.initials: F
authors.lastname: Al Sharif
authors.forename: H
authors.initials: H
authors.lastname: Al Zahrani
authors.forename: A
authors.initials: A
authors.lastname: Al Shanqeeti
authors.forename: P
authors.initials: P
authors.lastname: Seth
authors.forename: S
authors.initials: S
authors.lastname: Zaidi
authors.forename: M
authors.initials: M
authors.lastname: Morshed
authors.forename: K
authors.initials: K
authors.lastname: Al Anazi
authors.forename: G
authors.initials: G
authors.lastname: Mohamed
authors.forename: M
authors.initials: M
authors.lastname: Gyger
authors.forename: M
authors.initials: M
authors.lastname: Aljurf
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006504:Hepatic Veno-Occlusive Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D019653:Myeloablative Agonists / Q000009:adverse effects; D010865:Pilot Projects; D011446:Prospective Studies; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous / Q000009:adverse effects
chemical_list: D000893:Anti-Inflammatory Agents; D019653:Myeloablative Agonists; D008775:Methylprednisolone